Orchestra BioMed Holdings, Inc. OBIO PHARMA
Company Overview
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Why Investors Should Care
Revenue has grown at a 111.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $33.48M (+1169.2% YoY); net profit $-52.70M.
- Trailing 12 Months Year-on-year growth — revenue -89.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 111.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 111.62% |
| 1 Year: | -89.50% |
Stock Price Performance
| 1 Year: | +104.14% |
| 6 Months: | +16.27% |
| 3 Months: | +37.47% |
| 1 Month: | +28.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross8d ago
- RSI (14)63.88 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 111.6% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OBIO Orchestra BioMed Holdings, Inc. PHARMA | 5.43 | -6.46 | $326.37M | 0.00% | -52.80% | - | 111.62% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 866.00K | 401.00K | 1.16M | 1.16M | 915.00K | 419.00K | 620.00K | 778.00K | 987.00K | - | 868.00K | 836.00K | 861.00K | 30.92M | 110.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44.00K | 46.00K | 49.00K | 51.00K | 32.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 824.00K | 790.00K | 812.00K | 30.87M | 78.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.75M | 20.12M | 21.12M | 24.11M | 22.15M |
| Operating Income | -68.62K | -111.95K | -96.32K | -94.44K | -5.13M | -7.63M | -10.07M | -11.54M | -12.96M | -14.52M | -14.42M | -16.86M | -16.34M | - | -18.92M | -19.33M | -20.31M | 6.75M | -22.08M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.84M | -19.25M | -20.23M | 7.09M | -21.99M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.75M | -19.36M | -20.83M | 6.25M | -20.69M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -66.21K | -108.00K | -92.33K | -90.41K | -5.73M | -7.85M | -10.28M | -10.94M | -12.05M | -13.32M | -13.46M | -15.98M | -15.43M | - | -18.75M | -19.36M | -20.83M | 6.25M | -20.69M |
| Diluted EPS | - | - | 0.00 | 0.00 | -0.62 | -0.77 | -0.51 | -0.40 | -0.35 | -0.38 | -0.38 | -0.45 | -0.41 | - | -0.49 | -0.50 | -0.40 | - | -0.33 |
| R&D Expense | - | - | - | - | 3.47M | 5.03M | 5.90M | 8.25M | 8.50M | 8.56M | 9.11M | 11.13M | 11.60M | - | 13.48M | 13.85M | 14.03M | - | 15.78M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 3.53M | 2.76M | 2.64M | 33.48M |
| Cost of Revenue | - | 211.00K | 186.00K | 204.00K | 190.00K |
| Gross Profit | - | 3.32M | 2.57M | 2.43M | 33.29M |
| Operating Expenses | - | 35.98M | 54.08M | 66.73M | 85.10M |
| Operating Income | - | -32.66M | -51.51M | -64.30M | -51.81M |
| EBITDA | - | -32.44M | -51.22M | -63.99M | -51.23M |
| Interest Expense | 927.00K | - | - | - | 1.15M |
| Pretax Income | - | -33.61M | -49.12M | -61.02M | -52.70M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -33.61M | -49.12M | -61.02M | -52.70M |
| Diluted EPS | - | -1.06 | -1.48 | -1.66 | -1.11 |
| R&D Expense | - | 21.95M | 33.82M | 42.80M | 58.19M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | 162.16M | - | 95.57M | 95.21M | 76.17M | 114.86M |
| Current Assets | - | - | 84.69M | 89.11M | 69.17M | 107.91M |
| Cash & Equivalents | 2.03M | - | 19.78M | 30.56M | 22.26M | 34.69M |
| Inventory | - | - | 276.00K | 146.00K | 173.00K | 310.00K |
| Receivables | - | - | 96.00K | 99.00K | 92.00K | 95.00K |
| Total Liabilities | 5.72M | - | 43.04M | 27.17M | 43.22M | 61.29M |
| Current Liabilities | 118.96K | - | 18.57M | 11.21M | 16.21M | 16.74M |
| Long Term Debt | - | 3.67M | 9.49M | - | 14.29M | 14.27M |
| Total Debt | - | - | 11.87M | 1.69M | 16.53M | 15.96M |
| Total Equity | -3.56M | - | 52.53M | 68.04M | 32.96M | 53.57M |
| Shares Outstanding | - | - | 31.61M | 35.78M | 38.19M | 57.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -29.29M | -46.13M | -50.56M | -48.96M |
| Investing Cash Flow | - | -64.12M | 10.69M | 13.09M | -26.94M |
| Financing Cash Flow | - | 103.26M | 46.22M | 29.17M | 88.33M |
| Capital Expenditure | - | -591.00K | -78.00K | -289.00K | -489.00K |
| Free Cash Flow | - | -29.88M | -46.20M | -50.85M | -49.45M |
| Net Change in Cash | - | 9.85M | 10.78M | -8.30M | 12.43M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 94.0% | 93.3% | 92.3% | 99.4% |
| Operating Margin % | - | -924.3% | -1,866.2% | -2,437.5% | -154.7% |
| Net Margin % | - | -951.3% | -1,779.7% | -2,313.3% | -157.4% |
| ROE % | - | -64.0% | -72.2% | -185.2% | -98.4% |
| ROCE % | - | -42.4% | -61.3% | -107.2% | -52.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RTW Investments LP | 15.90% | 9.56M | $58.10M |
| 2 | Perceptive Advisors Llc | 8.38% | 5.04M | $30.63M |
| 3 | Blackrock Inc. | 4.18% | 2.51M | $15.26M |
| 4 | Vanguard Capital Management LLC | 3.37% | 2.02M | $12.30M |
| 5 | Geode Capital Management, LLC | 1.68% | 1.01M | $6.13M |
| 6 | Alyeska Investment Group, L.p. | 1.66% | 1.00M | $6.08M |
| 7 | Propel Bio Management, LLC | 1.49% | 896.70K | $5.45M |
| 8 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.07% | 642.15K | $3.90M |
| 9 | State Street Corporation | 0.86% | 516.05K | $3.14M |
| 10 | Rice, Hall, James & Associates LLC | 0.71% | 424.00K | $2.58M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OBIO
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partner…
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partner…
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, as…
Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partne…
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships wit…
Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
OBIO — Frequently Asked Questions
What is the current share price of Orchestra BioMed Holdings, Inc. (OBIO)?
As of 2026-09-19 21:16 PDT, Orchestra BioMed Holdings, Inc. (OBIO) trades at $5.43 on NasdaqGM. Its 52-week range is $2.35 to $5.66.
What is the market capitalisation of OBIO?
Orchestra BioMed Holdings, Inc. (OBIO) has a market capitalisation of $326.37M on NasdaqGM.
What is the P/E ratio of OBIO?
OBIO trades at a trailing price-to-earnings (P/E) ratio of -6.46. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 18.94.
Is OBIO a good stock to buy?
This page provides a data-driven analysis of Orchestra BioMed Holdings, Inc. (OBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.